home / stock / xncr / xncr news

XNCR News and Press, Xencor Inc. From 11/06/18

Stock Information
Company Name: Xencor Inc.
Stock Symbol: XNCR
Market: NASDAQ
Website: xencor.com
Menu
XNCR XNCR Quote XNCR Short XNCR News XNCR Articles XNCR Message Board
Get XNCR Alerts

News, Short Squeeze, Breakout and More Instantly...
XNCR - Xencor Q3 revenues $29M

Xencor (NASDAQ: XNCR ) Q3 results ($M): Revenues: 29.0 (from Novartis collaboration and $9M in milestone payments from Alexion). More news on: Xencor, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

XNCR - Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q3 2018 Results - Earnings Call Transcript

Xencor, Inc. (NASDAQ:XNCR) Q3 2018 Earnings Conference Call November 5, 2018 4:30 PM ET Executives Charles Liles - Associate Director and Head of Corporate Communications and Investor Relations Bassil Dahiyat - Co-Founder, CEO, President & Director Paul Foster – SVP,...

XNCR - Xencor beats by $0.57, beats on revenue

Xencor (NASDAQ: XNCR ): Q3 GAAP EPS of $0.05 beats by $0.57 . More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

XNCR - Xencor Reports Third Quarter 2018 Financial Results

MONROVIA, Calif. , Nov. 5, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for t...
XNCR - Xencor up 12% on positive XmAb 14045 data

Thinly trade Xencor ( XNCR +11.7% ) is up on below-average volume following its announcement initial data from a Phase 1 dose-escalation study evaluating XmAb 14045 in patients with relapsed/refractory acute myeloid leukemia (AML). The results will be presented at ASH next month. More ...

XNCR - Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting

MONROVIA, Calif. , Nov. 1, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced that initial data from its ongoin...

XNCR - Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018

MONROVIA, Calif. , Oct. 29, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it will re...
XNCR - Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement

NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CSG Systems International, Inc. (NASDAQ:CSGS), Zumiez Inc. (NASDAQ:ZUM...

XNCR - Key events next week - healthcare

Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...

XNCR - Premarket Losers as of 9:05 am (10/5/2018)

HSGX   -43%  on pricing public offering of common stock and warrants. More news on: Histogenics Corporation, KemPharm, Aytu BioScience, Inc., Stocks on the move, Top stock market news, , Read more ...

Previous 10 Next 10